The aim of this paper was to examine the efficacy and the safety of intraorbital administration of the monoclonal anti-CD20 antibody rituximab (RTX) to treat patients affected by thyroid-associated orbitopathy (TAO) unresponsive to conventional therapy.
Savino, G., Balia, L., Colucci, D., Battendieri, R., Gari, M., Corsello, S. M., Pontecorvi, A., Dickmann, A., Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series, <<MINERVA ENDOCRINOLOGICA>>, 2013; 38 (2): 173-179 [http://hdl.handle.net/10807/53730]
Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series
Savino, G;Balia, Laura;Colucci, Daniela;Battendieri, Remo;Gari, Mariangela;Corsello, Salvatore Maria;Pontecorvi, Alfredo;Dickmann, Anna
2013
Abstract
The aim of this paper was to examine the efficacy and the safety of intraorbital administration of the monoclonal anti-CD20 antibody rituximab (RTX) to treat patients affected by thyroid-associated orbitopathy (TAO) unresponsive to conventional therapy.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
